{
  "nctId": "NCT04423393",
  "briefTitle": "Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection",
  "officialTitle": "A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-3434",
  "protocolDocument": {
    "nctId": "NCT04423393",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2022-01-20",
    "uploadDate": "2023-10-20T11:34",
    "size": 1094965,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04423393/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE1"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 113,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-05-26",
    "completionDate": "2022-11-25",
    "primaryCompletionDate": "2022-10-24",
    "firstSubmitDate": "2020-05-25",
    "firstPostDate": "2020-06-09"
  },
  "eligibilityCriteria": {
    "criteria": "Healthy Volunteers:\n\nInclusion Criteria:\n\n* Male or female age 18 - 55\n* Weight 40-125 kg\n\nExclusion Criteria:\n\n* Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation\n* History or evidence of drug or alcohol abuse\n* History of allergic reactions to monoclonal antibodies or antibody fragments\n* History of anaphylaxis\n\nCHB Patients:\n\nInclusion Criteria:\n\n* Male or female age 18 - 65\n* Weight 40-125 kg\n* Chronic HBV infection for \\>/= 6 months\n\nExclusion Criteria:\n\n* Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation\n* Significant fibrosis or cirrhosis\n* History or evidence of drug or alcohol abuse\n* History of chronic liver disease from any cause other than chronic HBV infection\n* History of hepatic decompensation\n* History of anaphylaxis\n* History of allergic reactions to monoclonal antibodies or antibody fragments\n* History of immune complex disease\n* Active infection with HIV, HCV or hepatitis Delta virus",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Participants With Treatment-emergent Adverse Events (TEAEs)",
        "timeFrame": "Treatment-emergent period, which is up to Week 24 in part A, and up to Week 8 in part B/C/D"
      },
      {
        "measure": "Number of Participants With Clinical Laboratory Abnormalities",
        "timeFrame": "Up to 280 days post-dose"
      }
    ],
    "secondary": [
      {
        "measure": "Cmax",
        "description": "VIR-3434 Maximum Concentration in Serum",
        "timeFrame": "Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose"
      },
      {
        "measure": "Tmax",
        "description": "VIR-3434 time of Cmax in Serum",
        "timeFrame": "Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose"
      },
      {
        "measure": "AUClast",
        "description": "VIR-3434 under the curve from time 0 to last measurable Time",
        "timeFrame": "Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose"
      },
      {
        "measure": "t1/2",
        "description": "VIR-3434 apparent Elimination Half-life (t1/2) in serum",
        "timeFrame": "Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose"
      },
      {
        "measure": "Vz/F",
        "description": "VIR-3434 Volume of Distribution (SC only)",
        "timeFrame": "Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose"
      },
      {
        "measure": "Vz",
        "description": "VIR-3434 Volume of Distribution (IV only)",
        "timeFrame": "Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose"
      },
      {
        "measure": "CL/F",
        "description": "VIR-3434 Apparent serum clearance (SC only)",
        "timeFrame": "Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose"
      },
      {
        "measure": "CL",
        "description": "VIR-3434 Apparent serum clearance (IV only)",
        "timeFrame": "Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose"
      },
      {
        "measure": "Number of Participants With ADA to VIR-3434",
        "description": "Evaluate the immunogenicity of VIR-3434",
        "timeFrame": "Part A: Up to 168 days post-dose. Parts B-D: Up to 280 days post-dose"
      },
      {
        "measure": "Maximum Reduction of Serum HBsAg From Baseline (Day 1 Predose)",
        "description": "HBsAg reductions at nadir and Week 4",
        "timeFrame": "Parts B-D: pre-dose and 1, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose"
      },
      {
        "measure": "Part D Only: Maximum Change of HBV DNA From Baseline (Day 1 Predose)",
        "description": "HBV DNA reductions at nadir and Week 4",
        "timeFrame": "Parts B-D: pre-dose and 1, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose Parts B-D: pre-dose and 1, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose"
      },
      {
        "measure": "Titers (if Applicable) of ADA to VIR-3434",
        "description": "Evaluate the immunogenicity of VIR-3434",
        "timeFrame": "Part A: Up to 168 days post-dose. Parts B-D: Up to 280 days post-dose"
      },
      {
        "measure": "Cmax",
        "description": "VIR-3434 Maximum Concentration in Serum",
        "timeFrame": "Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose"
      },
      {
        "measure": "AUClast",
        "description": "VIR-3434 under the curve from time 0 to last measurable Time",
        "timeFrame": "Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 14,
      "otherCount": 0,
      "totalCount": 16
    },
    "studyDesign": {
      "phases": [
        "PHASE1"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:22.914Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}